Browsing category:

OTC and Compounding Product


Alkermes excitedly announced extremely positive study data from a Phase 3 trial of Aripiprazole. This randomized, placebo-controlled and double-blind study gleaned better than expected results, leading pharmaceutical executives at Alkermes to set a plan in motion for an NDA by the third quarter of 2014. As a long acting and injectable antipsychotic treatment Aripiprazole Lauroxil[…]

Read More

On March 25, 2014 Actavis and Valeant Pharmaceuticals announced the FDA approval of Metronidazole 1.3% gel for the antibiotic treatment of Bacterial Vaginosis. Bacterial Vaginosis, or BV, is an extremely common vaginal infection which commonly affects women between the ages of 15 and 44. An imbalance of normal bacteria in the vagina is the leading[…]

Read More

The National Institute for Health and Care Excellence {NICE} in the U.K. approved Bortezomib for multiple myeloma treatment on March 21, 2014. This serious, and often fatal blood cancer affects roughly 4500 patients in the U.K. each year. Multiple myeloma is projected to afflict about 24,000 new patients in the United States in 2014, with[…]

Read More

Positive Study Results As a common medication prescribed for post-menopausal women to treat and prevent osteoporosis, Raloxifene has now been recognized as a potential viable treatment for both breast and liver cancer. A recently released study, conducted at Oregon State University, demonstrated powerful data touting the use of Raloxifene to treat triple-negative breast cancer (TNBC)[…]

Read More

The recent approval of two low dosage strengths of Indomethacin have been a boon for Iroko Pharmaceuticals. The FDA approved their twenty and forty milligram doses of the popular nonsteroidal anti-inflammatory drug under the brand name Tivorbex. As easy to swallow capsules, the approval of the lower dose Indomethacin will likely lead to fewer adverse[…]

Read More

Rosuvastatin Calcium, known as the brand name Crestor, has a patent expiration of August 4, 2020. Recent study data revealed that patients who received the high potency statin Rosuvastatin after a heart attack had a high survival rate. This study from the Cardiovascular division at the University of Dundee Medical School compared Ezetimibe with higher[…]

Read More

Known as the brand name Clarinex, as well as Clarinex D 12 Hour, Desloratadine is a steadfast and tolerable treatment for allergies. Desloratadine offers anti-inflammatory benefits, as it is a selective H(1)-receptor antagonist. Known as a safe and effective antihistamine for both adults and children, it comes as no surprise that IMS Health released positive[…]

Read More

On June 4, 2013 Aqua Pharmaceuticals announced its acquisition of the brand name foam of Desonide, coined Verdeso, from Stiefel Pharmaceuticals. This announcement was extremely positive for Aqua Pharmaceuticals, as they already hold a thriving lineup of dermatologic products, such as Fluoroplex and Cordran. The addition of Verdeso, a foam formulation of Desonide, has filled[…]

Read More

The first topical steroid, Difluprednate, known as the brand name Durezol, continues to prove itself year after year. As a difluorinated derivative of prednisolone, Difluprednate has been indicated to treat both eye pain and inflammation after surgery, as well as anterior uveitis. A recent clinical trial published on June 18, 2013 indicated success for participants[…]

Read More

Fluticasone Propionate, which is currently short in supply, received a New Drug Application, or NDA at on July 31, 2013. Drug maker Perrigo announced the new drug application for fluticasone propionate lotion, 0.05%. This form of fluticasone propionate lotion is the generic equivalent to Cutivate Lotion, 0.05%. The use of the effectual and tolerable corticosteroid[…]

Read More